Successful amelioration of signs and symptoms of arthritis in patients with TNF-α-neutralizing agents has transformed RA treatment strategies quite significantly, which facilitated further research to target other inflammatory cytokines like IL-1, IL-6, and IL-17. This evidence concerns the gene TNF and rheumatoid arthritis.